IS7261A - N-adamantýlmetýlafleiður og milliefni sem lyfjablöndur og aðferðir til að framleiða þær - Google Patents
N-adamantýlmetýlafleiður og milliefni sem lyfjablöndur og aðferðir til að framleiða þærInfo
- Publication number
- IS7261A IS7261A IS7261A IS7261A IS7261A IS 7261 A IS7261 A IS 7261A IS 7261 A IS7261 A IS 7261A IS 7261 A IS7261 A IS 7261A IS 7261 A IS7261 A IS 7261A
- Authority
- IS
- Iceland
- Prior art keywords
- adamantylmethyl
- intermediates
- derivatives
- producing
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0103836A SE0103836D0 (sv) | 2001-11-16 | 2001-11-16 | Novel compounds |
| PCT/SE2002/002057 WO2003041707A1 (en) | 2001-11-16 | 2002-11-12 | N-adamantylmethyl derivates and intermediates as pharmaceutical compositions and processes for their preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IS7261A true IS7261A (is) | 2004-05-13 |
Family
ID=20286020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS7261A IS7261A (is) | 2001-11-16 | 2004-05-13 | N-adamantýlmetýlafleiður og milliefni sem lyfjablöndur og aðferðir til að framleiða þær |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US7129246B2 (is) |
| EP (1) | EP1448195B1 (is) |
| JP (1) | JP4559077B2 (is) |
| KR (1) | KR20040058290A (is) |
| CN (1) | CN1585640B (is) |
| AR (1) | AR037534A1 (is) |
| AT (1) | ATE344034T1 (is) |
| AU (1) | AU2002347741B2 (is) |
| BR (1) | BR0214142A (is) |
| CA (1) | CA2464863A1 (is) |
| CO (1) | CO5580747A2 (is) |
| DE (1) | DE60215851T2 (is) |
| DK (1) | DK1448195T3 (is) |
| ES (1) | ES2274110T3 (is) |
| HK (1) | HK1067048A1 (is) |
| HU (1) | HUP0402560A3 (is) |
| IL (1) | IL161693A0 (is) |
| IS (1) | IS7261A (is) |
| MX (1) | MXPA04004498A (is) |
| MY (1) | MY136430A (is) |
| NO (1) | NO20042155L (is) |
| NZ (1) | NZ532755A (is) |
| PL (1) | PL370855A1 (is) |
| PT (1) | PT1448195E (is) |
| RU (1) | RU2300525C2 (is) |
| SE (1) | SE0103836D0 (is) |
| TW (1) | TW200407297A (is) |
| UA (1) | UA77978C2 (is) |
| WO (1) | WO2003041707A1 (is) |
| ZA (1) | ZA200403682B (is) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI258462B (en) * | 1999-12-17 | 2006-07-21 | Astrazeneca Ab | Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same |
| GB0013737D0 (en) | 2000-06-07 | 2000-07-26 | Astrazeneca Ab | Novel compounds |
| SE0200920D0 (sv) * | 2002-03-25 | 2002-03-25 | Astrazeneca Ab | Novel compounds |
| SE0300480D0 (sv) | 2003-02-21 | 2003-02-21 | Astrazeneca Ab | Novel compounds |
| WO2004105797A1 (en) * | 2003-05-29 | 2004-12-09 | Astrazeneca Ab | A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine |
| BRPI0410739A (pt) * | 2003-05-29 | 2006-06-27 | Astrazeneca Ab | composição farmacêutica compreendendo um antagonista do receptor p2x7 e um fator de necrose tumoral (alfa) |
| EP1644042A1 (en) * | 2003-05-29 | 2006-04-12 | AstraZeneca AB | A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate |
| GB0312609D0 (en) * | 2003-06-02 | 2003-07-09 | Astrazeneca Ab | Novel compounds |
| KR100554155B1 (ko) * | 2003-06-09 | 2006-02-22 | 학교법인 포항공과대학교 | 금속/반도체 나노막대 이종구조를 이용한 전극 구조물 및그 제조 방법 |
| SE0302139D0 (sv) * | 2003-07-28 | 2003-07-28 | Astrazeneca Ab | Novel compounds |
| SE0302192D0 (sv) * | 2003-08-08 | 2003-08-08 | Astrazeneca Ab | Novel compounds |
| SE0302488D0 (sv) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | New combination |
| SA05260265A (ar) * | 2004-08-30 | 2005-12-03 | استرازينيكا ايه بي | مركبات جديدة |
| SE0402925D0 (sv) * | 2004-11-30 | 2004-11-30 | Astrazeneca Ab | Novel Compounds |
| CA2670636A1 (en) | 2006-11-27 | 2008-06-05 | H. Lundbeck A/S | Heteroaryl amide derivatives |
| MX2009010059A (es) * | 2007-03-22 | 2009-10-12 | Astrazeneca Ab | Derivados de quinolina para el tratamiento de enfermedades inflamatorias. |
| EA200970931A1 (ru) | 2007-04-10 | 2010-04-30 | Х. Лундбекк А/С | Аналоги гетероариламидов |
| US8106073B2 (en) | 2007-11-30 | 2012-01-31 | Astrazeneca Ab | Quinoline derivatives 057 |
| PL2105164T3 (pl) | 2008-03-25 | 2011-05-31 | Affectis Pharmaceuticals Ag | Nowi antagoniści P2X7R i ich zastosowanie |
| PT2243772E (pt) | 2009-04-14 | 2012-03-28 | Affectis Pharmaceuticals Ag | Novos antagonistas de p2x7r e sua utilização |
| EA201201548A1 (ru) | 2010-05-14 | 2013-05-30 | Эффектис Фармасьютиклз Аг | Новые способы получения p2x7r антагонистов |
| WO2012110190A1 (en) | 2011-02-17 | 2012-08-23 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| WO2012163456A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| WO2012163792A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| KR101995088B1 (ko) | 2011-07-22 | 2019-07-02 | 이도르시아 파마슈티컬스 리미티드 | Ｐ2ｘ7 수용체 길항제로서의 헤테로시클릭 아미드 유도체 |
| EP2804865B1 (en) | 2012-01-20 | 2015-12-23 | Actelion Pharmaceuticals Ltd. | Heterocyclic amide derivatives as p2x7 receptor antagonists |
| KR101576235B1 (ko) | 2012-11-30 | 2015-12-11 | 한국생명공학연구원 | 신규한 이치환 아다만틸 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 암 전이 억제용 약학적 조성물 |
| WO2014091415A1 (en) | 2012-12-12 | 2014-06-19 | Actelion Pharmaceuticals Ltd | Indole carboxamide derivatives as p2x7 receptor antagonists |
| TW201427945A (zh) | 2012-12-18 | 2014-07-16 | Actelion Pharmaceuticals Ltd | 作爲ｐ２ｘ７受體拮抗劑之吲哚羧醯胺衍生物 |
| US9388197B2 (en) | 2013-01-22 | 2016-07-12 | Actelion Pharmaceuticals Ltd. | Heterocyclic amide derivatives as P2X7 receptor antagonists |
| US9388198B2 (en) | 2013-01-22 | 2016-07-12 | Actelion Pharmaceuticals Ltd. | Heterocyclic amide derivatives as P2X7 receptor antagonists |
| CN104163795B (zh) * | 2014-08-19 | 2016-02-03 | 四川大学 | 盐酸烟酰美金刚胺溶剂合物、其制备方法和用途 |
| CN104628617B (zh) * | 2015-02-12 | 2016-04-06 | 佛山市赛维斯医药科技有限公司 | N-金刚烷酰胺类葡萄糖激酶活化剂、制备方法及其用途 |
| CN104628615B (zh) * | 2015-02-12 | 2016-04-06 | 佛山市赛维斯医药科技有限公司 | 含卤代苯的n-金刚烷酰胺类化合物、其制备方法及其用途 |
| CN104628616B (zh) * | 2015-02-12 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | 含对硝基苯基的n-金刚烷酰胺类化合物、其制备方法及用途 |
| CN104693084B (zh) * | 2015-02-12 | 2016-03-16 | 佛山市赛维斯医药科技有限公司 | 含腈基苯基的n-金刚烷酰胺类化合物、其制备方法及用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3352912A (en) * | 1963-07-24 | 1967-11-14 | Du Pont | Adamantanes and tricyclo[4. 3. 1. 1 3.8] undecanes |
| US3471491A (en) | 1967-08-28 | 1969-10-07 | Squibb & Sons Inc | Adamantyl-s-triazines |
| US3464998A (en) | 1968-03-04 | 1969-09-02 | Searle & Co | Adamantyl esters and amides of pyridinecarboxylic acids |
| GB1274652A (en) * | 1968-08-27 | 1972-05-17 | Lilly Industries Ltd | Adamantanyl-alkylamine derivatives and their preparation |
| US4027035A (en) * | 1968-08-27 | 1977-05-31 | Eli Lilly And Company | Therapeutic uses of adamantanealkylamine compounds |
| IL53441A0 (en) * | 1977-11-22 | 1978-01-31 | Teva Pharma | Methyladamantyl hydrazines their preparation and pharmaceutical compositions containing them |
| US4751292A (en) * | 1985-07-02 | 1988-06-14 | The Plant Cell Research Institute, Inc. | Adamantyl purines |
| WO1990010622A1 (en) * | 1989-03-10 | 1990-09-20 | Idemitsu Kosan Co. Ltd. | Pyridine derivatives and their salts, and insecticidal/acaricidal agent containing the same as active ingredient |
| PT720601E (pt) | 1993-08-10 | 2001-02-28 | Black James Foundation | Ligandos de receptores de gastrina e cck |
| FR2761358B1 (fr) * | 1997-03-27 | 1999-05-07 | Adir | Nouveaux composes de n-aryl piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| SE9704545D0 (sv) * | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| SE9704544D0 (sv) * | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| RU2254333C2 (ru) | 1999-04-09 | 2005-06-20 | Астразенека Аб | Производные адамантана, способ их получения, фармацевтическая композиция на их основе и способы лечения |
| GB0013737D0 (en) | 2000-06-07 | 2000-07-26 | Astrazeneca Ab | Novel compounds |
| SE0200920D0 (sv) | 2002-03-25 | 2002-03-25 | Astrazeneca Ab | Novel compounds |
-
2001
- 2001-11-16 SE SE0103836A patent/SE0103836D0/xx unknown
-
2002
- 2002-11-07 TW TW091132764A patent/TW200407297A/zh unknown
- 2002-11-12 BR BR0214142-6A patent/BR0214142A/pt not_active IP Right Cessation
- 2002-11-12 PL PL02370855A patent/PL370855A1/xx not_active Application Discontinuation
- 2002-11-12 WO PCT/SE2002/002057 patent/WO2003041707A1/en active IP Right Grant
- 2002-11-12 AU AU2002347741A patent/AU2002347741B2/en not_active Ceased
- 2002-11-12 US US10/495,711 patent/US7129246B2/en not_active Expired - Fee Related
- 2002-11-12 IL IL16169302A patent/IL161693A0/xx unknown
- 2002-11-12 DK DK02783941T patent/DK1448195T3/da active
- 2002-11-12 NZ NZ532755A patent/NZ532755A/en unknown
- 2002-11-12 JP JP2003543594A patent/JP4559077B2/ja not_active Expired - Fee Related
- 2002-11-12 MX MXPA04004498A patent/MXPA04004498A/es active IP Right Grant
- 2002-11-12 EP EP02783941A patent/EP1448195B1/en not_active Expired - Lifetime
- 2002-11-12 AT AT02783941T patent/ATE344034T1/de not_active IP Right Cessation
- 2002-11-12 KR KR10-2004-7007397A patent/KR20040058290A/ko not_active Application Discontinuation
- 2002-11-12 CA CA002464863A patent/CA2464863A1/en not_active Abandoned
- 2002-11-12 RU RU2004112780/04A patent/RU2300525C2/ru not_active IP Right Cessation
- 2002-11-12 CN CN028225171A patent/CN1585640B/zh not_active Expired - Fee Related
- 2002-11-12 HU HU0402560A patent/HUP0402560A3/hu unknown
- 2002-11-12 PT PT02783941T patent/PT1448195E/pt unknown
- 2002-11-12 DE DE60215851T patent/DE60215851T2/de not_active Expired - Lifetime
- 2002-11-12 ES ES02783941T patent/ES2274110T3/es not_active Expired - Lifetime
- 2002-11-14 MY MYPI20024270A patent/MY136430A/en unknown
- 2002-11-15 AR ARP020104406A patent/AR037534A1/es unknown
- 2002-12-11 UA UA20040503316A patent/UA77978C2/uk unknown
-
2004
- 2004-05-11 CO CO04043373A patent/CO5580747A2/es not_active Application Discontinuation
- 2004-05-13 IS IS7261A patent/IS7261A/is unknown
- 2004-05-13 ZA ZA200403682A patent/ZA200403682B/xx unknown
- 2004-05-25 NO NO20042155A patent/NO20042155L/no not_active Application Discontinuation
- 2004-12-20 HK HK04110069A patent/HK1067048A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IS7261A (is) | N-adamantýlmetýlafleiður og milliefni sem lyfjablöndur og aðferðir til að framleiða þær | |
| IS8024A (is) | Adamantanafleiður, aðferðir til að framleiða þær og lyfjablanda sem inniheldur þær | |
| IL162200A (en) | 17a - ALKYL - 17?? - OXY - ESTRATRIENES, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND INTERMEDIATES FOR THEIR PRODUCTION | |
| IS7543A (is) | Bensóþíadíasepínafleiður, aðferðir til framleiðslu þeirra og lyfjablöndur sem innihalda þær | |
| GB0321607D0 (en) | Manufacture of pharmaceutical compositions | |
| DK2092935T3 (da) | Farmaceutiske sammensætninger til behandling astma | |
| FI20011478A (fi) | Farmaseuttinen koostumus | |
| IS7226A (is) | Fjölbrigða form af rimonabant, framleiðsluaðferð og lyfjasamsetningar sem innihalda það | |
| ZA200602840B (en) | Pharmaceutical compositions comprising malonamide derivatives for decreasing sebum production | |
| EE200300589A (et) | Ravimkoostised | |
| NO20052859D0 (no) | Fremgangsmate for fremstilling av resperidon og intermediater derav | |
| GB0303609D0 (en) | Novel therapeutic method and compositions | |
| IS8164A (is) | Hringtengdar amínafleiður, aðferðir til að framleiða þær og lyfjablöndur sem innihalda þær | |
| FI20022128A0 (fi) | Farmaseuttinen koostumus | |
| EP1569973A4 (en) | MICROGEL COMPOSITION AND METHOD FOR THE PRODUCTION THEREOF | |
| IS7424A (is) | Oxasólídínónafleiður, aðferðir til að framleiða þær og lyfjablöndur sem innihalda þær | |
| EP1482937A4 (en) | NOVEL TYLOINDICINS AND COMPOUNDS THEREFOR, PHARMACEUTICAL COMPOSITIONS AND METHODS | |
| NO20013735D0 (no) | Fremgangsmåte til fremstilling av di-iso-butaner, di-iso- butener og di-n-butener fra feltbutaner | |
| IS7008A (is) | Nýjar píperidínkarboxamíð afleiður, aðferð til framleiðslu þeirra og lyfjasamsetningar sem innihalda þær | |
| DK1511724T3 (da) | Fremgangsmåde til fremstilling af thioalkylaminderivater | |
| NO20044332L (no) | Forbedret fremgangsmate for fremstilling av nevirapine | |
| EE200300465A (et) | Püridoindolooni derivaatidel põhinevad farmatseutilised kompositsioonid | |
| GB0303600D0 (en) | Novel therapeutic method and compositions | |
| NO20044164L (no) | Farmasoytiske sammensetninger | |
| ITMI20011734A0 (it) | Derivanti tassanici e procedimenti per la loro preparazione |